The FinTech Hub
Source: Live Mint Sun Pharmaceutical Industries Ltd’s latest acquisition of US-based Checkpoint Therapeutics, Inc. is good news for its speciality business–an area of focus. Checkpoint is an immunotherapy and targeted oncology company. The move will help Sun Pharma expand its portfolio of products for skin cancer within the speciality business. The key product owned by…
Source: Live Mint Sun Pharmaceutical Industries Ltd. has announced the acquisition of Nasdaq-listed Checkpoint Therapeutics, Inc., an immunotherapy and targeted oncology company, in a $355 million cash deal. The acquisition will bolster Sun Pharma’s onco-dermatology portfolio, adding Checkpoint’s recently FDA-approved cancer drug, UNLOXCYT (cosibelimab-ipdl), to its pipeline. The deal, expected to close in the second…
Source: Live Mint Sun Pharma Q2 Results: Sun Pharmaceutical Industries Ltd on Monday reported an 28% year-on-year rise in its consolidated net profit for the fiscal’s second quarter ended September (Q2FY24) to ₹3,040.16 crore. The company had reported a profit of ₹23,755.1 crore in the year-ago period. Sequentially, the consolidated net profit was up 7.2%….
Source: Business Standard 4 min read Last Updated : Sep 27 2024 | 3:02 PM IST Shares of Sun Pharmaceutical Industries hit a new high of Rs 1,952, as they rallied 3 per cent on the BSE in Friday’s intra-day trade in an otherwise subdued market. The rally in the stock came after UBS…
Source: Business Standard 3 min read Last Updated : Sep 27 2024 | 9:11 AM IST Global brokerage UBS has raised concerns about weakening trends in the Indian and the US pharmaceutical markets. In its recent coverage initiation report, UBS said the pace of a decline in the US generic market is likely to…
